Prostate Cancer - Results from #1540

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. January 10, 2024

Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular Correlates. January 10, 2024

Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer. January 10, 2024

Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging. January 10, 2024

Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. January 10, 2024

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics January 9, 2024

Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. January 9, 2024

A qualitative study of barriers and facilitators for health behavior change in low-income men with prostate cancer. January 9, 2024

Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI. January 9, 2024

The Oncological and Functional Prognostic Value of Unconventional Histology of Prostate Cancer in Localized Disease Treated with Robotic Radical Prostatectomy: An International Multicenter 5-Year Cohort Study. January 9, 2024

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. January 9, 2024

Tissue contamination challenges the credibility of machine learning models in real world digital pathology. January 9, 2024

27-hydroxycholesterol and DNA damage repair: implication in prostate cancer. January 9, 2024

CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3. January 9, 2024

Adverse events and costs among non-metastatic castration-resistant prostate cancer patients. January 8, 2024

Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer. January 8, 2024

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. January 8, 2024

Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. January 8, 2024

Clinical and functional outcomes for risk-appropriate treatments for prostate cancer. January 8, 2024

Co-designing an online treatment decision aid for men with low-risk prostate cancer: Navigate. January 8, 2024

Page 78 of 1436